Shanghai Allist Pharmaceuticals Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Allist Pharmaceuticals Co., Ltd.
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
Against the prevailing headwinds in the biotech sector, two Chinese firms are bucking the trend of pipeline reorganization by eyeing the potential acquisition of assets from external partners to expand into more modalities and therapeutic areas.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Following disruptions in the second quarter from lockdowns around China, major Chinese firms BeiGene and Junshi reported strong double-digit sales gains for anti-PD-1 antibodies in the third quarter. Revenues at others including Hengrui, Zai Lab and Allist also shone during the period.
- Drug Delivery
- Controlled Release
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Allist Pharmaceuticals, Inc.,
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.